|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
|
3.1 Tabac
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
Pfizer bets up to $1B on BioAtla's approach to immuno-oncology - FierceBiotech
|
|
|
|
|
|
Under
the agreement, BioAtla is handing over some of its conditionally active
biologics, or CABs, which are immunotherapeutics that can be switched
on in the presence of certain antigens. And Pfizer is bringing a stable
of antibody-drug conjugates, or ADCs, which use antibodies to ferry
treatments to specific targets.
|
|
|
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
What chemo patients should know about cap to prevent hair loss [STAT]
|
|
|
|
|
|
The
device was tested in patients with breast cancer, and the FDA
spokesperson said that they can only approve uses based on data
available to them. Scalp cooling can’t be used for blood-based cancers
such as myeloma, leukemia, or lymphoma, according to Macmillan Cancer
Support, because there is a high risk that cancer cells in the scalp’s
blood vessels could be shielded by the cold.
|
|
|
|
|
|
|
|
|
5.5 ASCO
|
|
|
|
5.7.1 SABCS-communiqués
|
|
|
|
|
5.7.3 SABCS-AACR
|
|
|
|
|
5.8 ASH
|
|
|
Veni, Vedi, Vene? Venetoclax Hopes to Conquer CLL [The OBR Blog]
|
|
|
|
|
|
Certainly
the high response rates are difficult to ignore, but if the
administration is viewed as cumbersome, physicians may be hesitant to
adopt venetoclax into their treatment algorithm, particularly in certain
patient populations such as the elderly, who are at an increased risk
of TLS and are associated with comorbidities.
|
|
|
|
|
|
|
At Hematological Meeting, More Than Just Biotech Data Runs Blood Red [Xconomy]
|
|
|
|
|
|
Last
year, at the conference in San Francisco, strong early data in new
treatments for blood cancers and beta thalassemia helped buoy an already
bullish market for biotech.
This year, biotech markets are depressed, and investors are in no mood
to see glasses half full, punishing companies for not meeting
unrealistic expectations, or, it seems, for just being biotech
companies.
|
|
|
|
|
|
|
5.8.2 ASH - Pharma
|
|
|
|
|
5.8.4 ASH - CAR T
|
|
|
|
ASH – CAR-T struggles to travel beyond leukaemia [EP Vantage]
|
|
|
|
|
|
If
ASH was another scientific meeting where interest in CAR-T therapies
mounted, an obvious theme was just how much more work still needs to be
done to get beyond the relatively accessible low-hanging fruit of acute
lymphoblastic leukaemia (ALL).
|
|
|
|
|
|
|
|
5.8.5 ASH - Myélome multiple
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
Bill creating more orphan drugs would cost consumers billions [STAT]
|
|
|
|
|
|
Specifically,
the bill would allow drug makers to repurpose existing medications for
new uses and receive orphan designations. And this would confer an extra
six months of marketing exclusivity. Public Citizen maintains this
passage in the law amounts to a costly “monopoly protection.”
|
|
|
|
|
|
|
6.11 Patients
|
|
|
Online symptom monitoring benefits cancer patients [Reuters]
|
|
|
|
|
|
Researchers
found that patients who used a website to report their symptoms had
better quality of life, were less likely to go to the emergency room,
stayed on treatment longer and survived longer than people who were just
monitored by their doctors.
|
|
|
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
|
6.9 Controverses
|
|
|
|